oral cyclosporine a immune tolerance agent and oral lansoprazole proton pump inhibitor to enhance beta cell regeneration and insulin independence in type 1 diabetes mellitus clinical trial intelligence

A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate the Safety and Efficacy in Diminishing Insulin Requirements Utilizing Oral Cyclosporine With Oral Lansoprazole in Children and Adults With Existing Type 1 Diabetes Mellitus

Perle Bioscience, Inc. is investigating a novel combination therapy for Type 1 Diabetes Mellitus that leverages two FDA-approved drugs: Cyclosporine A and Lansoprazole. The potential to achieve insulin independence in patients could address a significant unmet need in the diabetes market, which is projected to grow substantially due to increasing prevalence. However, the study has been withdrawn prior to patient enrollment, which raises concerns regarding the feasibility of the trial design or potential regulatory hurdles. Competitive analysis indicates that while there are various therapies in development for Type 1 Diabetes, none have successfully sustained insulin independence, positioning this combination therapy as a potentially innovative approach if proven effective.

Matched by target_normalized: Oral Cyclosporine A (immune tolerance agent) and Oral Lansoprazole (proton-pump inhibitor) to enhance beta cell regeneration and insulin independence in Type 1 Diabetes Mellitus.